Clinical trial site criticizes Northwest Bio over its press releases

|About: Northwest Biotherapeut... (NWBO)|By:, SA News Editor

Dr. Buzdar says, "I have read the information that the company has put in the public domain. It is extremely unusual and inappropriate." He terms the company's disclosures inappropriate because injecting a tumor with any substance can cause regression due to necrosis-causing inflammation. He says, " is a tremendous leap to say that this is a real response."